By: IPP Bureau
Last updated : November 15, 2025 11:12 am
The observations are procedural in nature and will be responded to within the stipulated time
The United States Food and Drug Administration (US FDA) inspected Unit-II, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Bhiwadi, Alwar, Rajasthan, from November 3 -14, 2025.
The inspection concluded with 9 observations. The observations are procedural in nature and will be responded to within the stipulated time.
The company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.